The prognostic value of MR-proadrenomedullin in patients with acute coronary syndrome complicated by cardiogenic shock

Supel, Karolina; Kacprzak, Michał; Zielińska, Marzenna

doi:10.1080/1354750x.2016.1252962

Cited by 9 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Based on this, we hypothesised that biomarkers reflecting these processes could be elevated in patients in patients developing CS in their 'pre-shock' phase. Biomarkers reflecting these processes were selected based on previous studies showing that natriuretic peptides (NPs), 6,7 copeptin, 22,23 ST2 14 and MRproADM 7,12 were higher in patients suffering from critical heart disease and associated with poor outcome. Our findings suggest that these processes are ongoing in patients at risk of developing late CS.…”

Section: Discussionmentioning

confidence: 99%

“…10 Adrenomedullin (ADM) has a vasodilatory effect, 11 and the plasma concentration of the stable mid-regional pro-adrenomedullin (MRproADM) fragment has been found to be elevated in CS patients. 12 An increased systemic inflammatory response may cause inappropriate vasodilation in CS patients 4 and inflammatory biomarkers have been found to be elevated in STEMI patients with CS compared to non-CS patients. 13 Recently, soluble stimulation-2 (ST2), a receptor from the interleukin (IL)-1 receptor family, has been found in increased concentrations in patients with CS compared to STEMI patients without CS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction

Frydland

Møller

Lindholm

et al. 2020

European Heart Journal. Acute Cardiovascular Care

View full text Add to dashboard Cite

Background: Cardiogenic shock complicating ST-elevation myocardial infarction is characterised by progressive left ventricular dysfunction causing inflammation and neurohormonal activation. Often, cardiogenic shock develops after hospital admission. Whether inflammation and a neurohormonal activation precede development of clinical cardiogenic shock is unknown. Methods and results: In 93% of 2247 consecutive patients with suspected ST-elevation myocardial infarction admitted at two tertiary heart centres, admission plasma levels of pro-atrial natriuretic peptide, copeptin, mid-regional pro-adrenomedullin and stimulation-2 were measured on hospital admission. Patients were stratified according to no cardiogenic shock development and cardiogenic shock developed before (early cardiogenic shock) or after (late cardiogenic shock) leaving the catheterization laboratory. In total, 225 (10%) patients developed cardiogenic shock, amongst these patients late cardiogenic shock occurred in 64 (2.9%). All four biomarkers were independently associated with the development of late cardiogenic shock (odds ratio per two-fold increase in risk: 1.19–3.13) even when adjusted for the recently developed Observatoire Régional Breton sur l’Infarctus risk score for prediction of late cardiogenic shock development. Furthermore, pro-atrial natriuretic peptide, copeptin and mid-regional pro-adrenomedullin, but not stimulation-2, added significant predictive information, when added to the Observatoire Régional Breton sur l’Infarctus risk score (area under the receiver-operating characteristic curve, pro-atrial natriuretic peptide: 0.87, p=0.0008; copeptin: 0.86, p<0.05; mid-regional pro-adrenomedullin: 0.88, p=0.006). Conclusions: Pro-atrial natriuretic peptide, copeptin, mid-regional pro-adrenomedullin and stimulation-2 admission plasma concentration were associated with late cardiogenic shock development in patients admitted with suspected ST-elevation myocardial infarction. Pro-atrial natriuretic peptide, mid-regional pro-adrenomedullin and copeptin had independent predictive value for late cardiogenic shock development.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction

Frydland

Møller

Lindholm

et al. 2020

European Heart Journal. Acute Cardiovascular Care

View full text Add to dashboard Cite

show abstract

“…The present study showed that high bio-ADM at ICU admission in patients with CS complicating AMI was associated with increased mortality at 30 days. There have been several studies investigating the prognostic impact of adrenomedullin in patients with CS [ 30 , 31 , 32 ]. However, the majority of these studies used a stable fragment of the precursor molecule, mid-regional pro-ADM (MR-proADM) [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial

Takagi

Lévy

Kimmoun

et al. 2021

JCM

View full text Add to dashboard Cite

Aims: Bioactive adrenomedullin (bio-ADM) was recently shown to be a prognostic marker in patients with acute circulatory failure. We investigate the association of bio-ADM with organ injury, functional impairment, and survival in cardiogenic shock (CS). Methods: OptimaCC was a multicenter and randomized trial in 57 patients with CS. In this post-hoc analysis, the primary endpoint was to assess the association between bio-ADM and 30-day all-cause mortality. Secondary endpoints included adverse events and parameters of organ injury or functional impairment. Results: Bio-ADM values were higher in 30-day non-survivors than 30-day survivors at inclusion (median (interquartile range) 67.0 (54.6–142.9) pg/mL vs. 38.7 (23.8–63.6) pg/mL, p = 0.010), at 24 h (p = 0.012), and up to 48 h (p = 0.027). Using a bio-ADM cutoff of 53.8 pg/mL, patients with increased bio-ADM had a HR of 3.90 (95% confidence interval 1.43–10.68, p = 0.008) for 30-day all-cause mortality, and similar results were observed even after adjustment for severity scores. Patients with the occurrence of refractory CS had higher bio-ADM value at inclusion (90.7 (59.9–147.7) pg/mL vs. 40.7 (23.0–64.7) pg/mL p = 0.005). Bio-ADM values at inclusion were correlated with pulmonary vascular resistance index, estimated glomerular filtration rate, and N-terminal pro-B-type natriuretic peptide (r = 0.49, r = –0.47, and r = 0.64, respectively; p < 0.001). Conclusions: In CS patients, the values of bio-ADM are associated with some parameters of organ injury and functional impairment and are prognostic for the occurrence of refractory CS and 30-day mortality.

show abstract

“…Additionally, ADM involves in dilation of the coronary, inhibition of vascular remodeling and reduction of fibroblast proliferation and extracellular matrix synthesis, which may further contribute to reduction of infarct size, ischemia-reperfusion injury, and ischemia-induced arrhythmias [34]. Mid-regional pro-adrenomedullin (MR-proADM), a surrogate marker for adrenomedullin, has been reported to be a risk factor for the loss of renal function in patients with T2DM and be a predictor of in-hospital mortality in patients with acute MI complicated by cardiogenic shock [35,36]. NFIL3 (nuclear factor IL-3; E4 promoter-binding protein 4, E4BP4) is a D-box negative regulator and oscillates anti-phase to DBP, a D-box positive regulator [24].…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic Analysis of the Association Between Diabetes Mellitus and Myocardial Infarction

Song

You

Wang

et al. 2018

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

The prognostic value of MR-proadrenomedullin in patients with acute coronary syndrome complicated by cardiogenic shock

Abstract: Elevated plasma level of MR-proADM, determined 24 h after diagnosis of CS could be a predictor of in-hospital mortality in patients with AMI complicated by CS.

Cited by 9 publications

References 36 publications

Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction

Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction

Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial

Transcriptomic Analysis of the Association Between Diabetes Mellitus and Myocardial Infarction

Contact Info

Product

Resources

About